Last reviewed · How we verify

Influsplit SSW® — Competitive Intelligence Brief

Influsplit SSW® (Influsplit SSW®) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated split-virion influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated split-virion influenza vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Influsplit SSW® (Influsplit SSW®) — GlaxoSmithKline. Influsplit SSW is an inactivated split-virion influenza vaccine that stimulates immune response against seasonal influenza strains.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Influsplit SSW® TARGET Influsplit SSW® GlaxoSmithKline phase 3 Inactivated split-virion influenza vaccine
H5N1 vaccine (Arepanrix) H5N1 vaccine (Arepanrix) Canadian Immunization Research Network marketed inactivated split-virion influenza vaccine with adjuvant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated split-virion influenza vaccine class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Influsplit SSW® — Competitive Intelligence Brief. https://druglandscape.com/ci/influsplit-ssw. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing